Success Metrics

Clinical Success Rate
95.0%

Based on 38 completed trials

Completion Rate
95%(38/40)
Active Trials
2(4%)
Results Posted
71%(27 trials)
Terminated
2(4%)

Phase Distribution

Ph early_phase_1
1
2%
Ph phase_4
11
21%
Ph not_applicable
18
34%
Ph phase_2
9
17%
Ph phase_3
7
13%
Ph phase_1
6
11%

Phase Distribution

7

Early Stage

9

Mid Stage

18

Late Stage

Phase Distribution52 total trials
Early Phase 1First-in-human
1(1.9%)
Phase 1Safety & dosage
6(11.5%)
Phase 2Efficacy & side effects
9(17.3%)
Phase 3Large-scale testing
7(13.5%)
Phase 4Post-market surveillance
11(21.2%)
N/ANon-phased studies
18(34.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.4%

38 of 45 finished

Non-Completion Rate

15.6%

7 ended early

Currently Active

2

trials recruiting

Total Trials

53

all time

Status Distribution
Active(2)
Completed(38)
Terminated(7)
Other(6)

Detailed Status

Completed38
Withdrawn5
unknown5
Terminated2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
53
Active
2
Success Rate
95.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.9%)
Phase 16 (11.5%)
Phase 29 (17.3%)
Phase 37 (13.5%)
Phase 411 (21.2%)
N/A18 (34.6%)

Trials by Status

terminated24%
recruiting12%
completed3872%
withdrawn59%
active_not_recruiting12%
suspended12%
unknown59%

Recent Activity

Clinical Trials (53)

Showing 20 of 53 trialsScroll for more
NCT03890666Phase 4

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

Completed
NCT06563102Phase 4

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

Completed
NCT04901715Early Phase 1

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

Completed
NCT05819541Phase 2

Treating Exacerbations of Asthma With Oral Montelukast in Children

Recruiting
NCT02797275Phase 4

Secondhand Smoke Respiratory Health Study

Active Not Recruiting
NCT03137303Phase 3

Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)

Completed
NCT01880723Not Applicable

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

Completed
NCT04184609Phase 4

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes

Withdrawn
NCT04677959Phase 4

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

Completed
NCT00308685Phase 3

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

Completed
NCT05173584Phase 4

Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.

Unknown
NCT00577655Phase 3

Albuterol HFA MDI in Pediatric Participants With Asthma

Completed
NCT03270332Phase 2

Effect of Inhaled Albuterol in Pulmonary Hypertension

Completed
NCT02566902Not Applicable

Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

Completed
NCT01951378Phase 4

Comparison of Nebulizers in ED in Pediatric Asthma Patients

Terminated
NCT02802111Not Applicable

Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults

Completed
NCT02573870Phase 2

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Completed
NCT03430505Not Applicable

Effects of Noninvasive Ventilation Compared to Salbutamol

Completed
NCT01885936Phase 1

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

Completed
NCT01859624Phase 1

Albuterol in Individuals With Late Onset Pompe Disease (LOPD)

Completed

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
53